Chronic Lymphocytic Leukemia

Narendranath Epperla, MD, MS, discusses the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia.

Zanubrutinib continued to induce deep responses with acceptable tolerability in patients with relapsed/refractory chronic lymphocytic leukemia, including those with high-risk cytogenetics.

Paul M. Barr, MD, discusses the next steps of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Peter Hillmen, MD, PhD, discusses results reported with acalabrutinib in patients with chronic lymphocytic leukemia, as demonstrated in a phase 3 trial.

The fixed-dose combination of the BCL-2 inhibitor venetoclax and the humanized anti-CD20 monoclonal antibody obinutuzumab continued to confer a progression-free survival advantage over chlorambucil plus obinutuzumab for patients with previously untreated chronic lymphocytic leukemia.

Othman Al-Sawaf, MD, discusses the efficacy of venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia, as demonstrated in the phase 3 CLL14 trial.

Zanubrutinib induced superior response and progression-free survival rates, as well as lower rates of atrial fibrillation/flutter than ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

John C. Byrd, MD, discusses the rationale for the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the rationale to evaluate lisaftoclax in chronic lymphocytic leukemia.

The European Medicines Agency has granted marketing authorization to duvelisib for single-agent use in patients with relapsed/refractory chronic lymphocytic leukemia who have previously received at least 2 therapies or those with follicular lymphoma whose disease is refractory to at least 2 previous systemic therapies.

Ibrutinib plus venetoclax produced a complete response and complete response with incomplete bone marrow recovery rate of 56% in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.

TG-1701 demonstrated encouraging clinical and pharmacodynamic activity at all dose levels in patients with B-cell malignancies.

Single-agent ibrutinib given in the first-line setting sustained a progression-free survival and overall survival benefit compared with chlorambucil as therapy for patients with chronic lymphocytic leukemia at 7-year follow-up.

Cirmtuzumab and ibrutinib led to reported high overall response rates in patients with mantle cell lymphoma or chronic lymphocytic leukemia.

Sameem Abedin, MD, discusses the need for risk stratification prior to giving chemoimmunotherapy to patients with chronic lymphocytic leukemia.

Patients with chronic lymphocytic leukemia and single-hit TP53 mutations derived long-term responses with ibrutinib monotherapy, whereas patients with multi-hit TP53 aberrations had shortened progression-free survival.

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.

The combination of ibrutinib and venetoclax were found to act on distinct subpopulations of chronic lymphocytic leukemia that have different proliferative capacities in an ex vivo model of the disease, suggesting that the dual-targeted approach has the potential to eradicate residual disease in patients with CLL.

Omar Alkharabsheh, MD, discusses remaining challenges in high-risk chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD, MS, discusses treatment options for patients with chronic lymphocytic leukemia who harbor TP53 mutations or 17p deletions.

Omar Alkharabsheh, MD, discusses emerging treatment options in chronic lymphocytic leukemia.

Patient enrollment has commenced for the randomized phase 3 ULTRA-V trial, which will evaluate the efficacy of a time-limited combination of umbralisib plus ublituximab and venetoclax vs continuous umbralisib/ublituximab in patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD, MS, discusses factors to consider when selecting between BCL-2 inhibitors and BTK inhibitors in chronic lymphocytic leukemia.

Zanubrutinib demonstrated noninferiority in objective response rates and a trend toward improved progression-free survival when compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Mazyar Shadman, MD, discusses the emergence of third-generation BTK inhibitors in chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD, MS, discusses treatment considerations for patients with chronic lymphocytic leukemia.

Jacqueline Claudia Barrientos, MD, MS, discusses the shift away from chemoimmunotherapy in chronic lymphocytic leukemia.

Kerry A. Rogers, MD, discusses the safety profile of the combination of ianalumab plus ibrutinib, in patients with chronic lymphocytic leukemia.